NCT03749187 - BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 3, 2019

Primary Completion Date

June 30, 2026

Study Completion Date

July 30, 2029

Conditions

GlioblastomaIDH1 Gene MutationIDH2 Gene MutationLow Grade GliomaMalignant GliomaRecurrent GlioblastomaRecurrent WHO Grade II GliomaRecurrent WHO Grade III GliomaWHO Grade II GliomaWHO Grade III Glioma

Interventions

DRUG

PARP Inhibitor BGB-290

Given PO

DRUG

Temozolomide (TMZ)

Given PO

Trial Locations (11)

19104

RECRUITING

Children's Hospital of Philadelphia, Philadelphia

21287

RECRUITING

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

27710

RECRUITING

Duke University Medical Center, Durham

38105

RECRUITING

St. Jude Children's Research Hospital, Memphis

63110

RECRUITING

Washington University School of Medicine, St Louis

90027

RECRUITING

Children's Hospital Los Angeles, Los Angeles

94143

RECRUITING

University of California, San Francisco, San Francisco

97239

RECRUITING

Oregon Health and Science University, Portland

06520

RECRUITING

Yale University, New Haven

02215

RECRUITING

Dana-Farber Cancer Institute, Boston

07601

RECRUITING

Joseph M. Sanzari Children's Hospital at Hackensack University Medical Center, Hackensack

All Listed Sponsors

collaborator

BeiGene USA, Inc.

INDUSTRY

lead

University of California, San Francisco

OTHER